ES2084190T3 - Utilizacion de agentes protectores contra especies de oxigeno reactivas. - Google Patents

Utilizacion de agentes protectores contra especies de oxigeno reactivas.

Info

Publication number
ES2084190T3
ES2084190T3 ES91920537T ES91920537T ES2084190T3 ES 2084190 T3 ES2084190 T3 ES 2084190T3 ES 91920537 T ES91920537 T ES 91920537T ES 91920537 T ES91920537 T ES 91920537T ES 2084190 T3 ES2084190 T3 ES 2084190T3
Authority
ES
Spain
Prior art keywords
oxygen species
reactive oxygen
protective agents
agents against
against reactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91920537T
Other languages
English (en)
Inventor
Grace H W Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24413043&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2084190(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2084190T3 publication Critical patent/ES2084190T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

USO DE UNO O MAS AGENTES PROTECTORES SELECCIONADOS DEL GRUPO DE FACTORES DE NECROSIS DEL TUMOR ALFA Y BETA, HORMONA DEL CRECIMIENTO, IL-1 Y FACTOR D PARA LA PRODUCCION DE UNA COMPOSICION APROPIADA PARA LA PROTECCION, INHIBICION Y PREVENCION DE LOS EFECTOS PERJUDICIALES DE ESPECIES CON OXIGENO REACTIVO, Y ADMINISTRACION DE UNA CANTIDAD EFICAZ DEL AGENTE O AGENTES PROTECTORES. SE DESCRIBEN LOS TRATAMIENTOS DE TEJIDOS Y ORGANOS QUE HAN DE SER TRANSPLANTADOS. SE DESCRIBEN SOLUCIONES DE PERFUSION Y LA PREPARACION DE TEJIDOS PERFUSADOS, SAJADOS. MORTALIDAD (%) TIEMPO(DIAS)
ES91920537T 1990-10-25 1991-10-21 Utilizacion de agentes protectores contra especies de oxigeno reactivas. Expired - Lifetime ES2084190T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60285090A 1990-10-25 1990-10-25

Publications (1)

Publication Number Publication Date
ES2084190T3 true ES2084190T3 (es) 1996-05-01

Family

ID=24413043

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91920537T Expired - Lifetime ES2084190T3 (es) 1990-10-25 1991-10-21 Utilizacion de agentes protectores contra especies de oxigeno reactivas.

Country Status (9)

Country Link
EP (1) EP0554381B2 (es)
JP (2) JPH06503320A (es)
AT (1) ATE133073T1 (es)
CA (1) CA2092718C (es)
DE (1) DE69116565T2 (es)
DK (1) DK0554381T3 (es)
ES (1) ES2084190T3 (es)
GR (1) GR3019229T3 (es)
WO (1) WO1992007578A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69423806T2 (de) * 1993-01-22 2000-08-17 Kanegafuchi Chemical Ind Therapeutisches Agens für NIDDM
US5935924A (en) * 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
US5661122A (en) * 1994-04-15 1997-08-26 Genentech, Inc. Treatment of congestive heart failure
AUPO263696A0 (en) * 1996-09-27 1996-10-24 Walter And Eliza Hall Institute Of Medical Research, The A process for culturing cells
SE9703929D0 (sv) * 1996-11-22 1997-10-28 Pharmacia & Upjohn Ab Therapeutical use and method
EP1043027A1 (en) * 1999-04-08 2000-10-11 Applied Research Systems ARS Holding N.V. Treatment of multiple sclerosis with a combination of Interferon and Growth hormone
US7674453B2 (en) * 2002-02-06 2010-03-09 Ares Trading Sa Tumor necrosis factor combined with interferon in demyelinating diseases
AU2003254902A1 (en) * 2002-08-09 2004-02-25 Kaken Pharmaceutical Co., Ltd. Myocardial cell protecting agents
MXPA05003869A (es) * 2002-10-08 2005-06-22 Ares Trading Sa El uso de citocina capaz de enlazarse a la proteina de union a interleucina-18, y de inhibir la actividad de una segunda citocina.
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof

Also Published As

Publication number Publication date
JP2002179590A (ja) 2002-06-26
AU8941291A (en) 1992-05-26
WO1992007578A1 (en) 1992-05-14
CA2092718C (en) 2007-08-07
GR3019229T3 (en) 1996-06-30
ATE133073T1 (de) 1996-02-15
JPH06503320A (ja) 1994-04-14
CA2092718A1 (en) 1992-04-26
EP0554381B2 (en) 2000-04-26
DK0554381T3 (da) 1996-04-09
DE69116565T2 (de) 1996-08-01
EP0554381B1 (en) 1996-01-17
EP0554381A1 (en) 1993-08-11
DE69116565D1 (de) 1996-02-29
AU661463B2 (en) 1995-07-27

Similar Documents

Publication Publication Date Title
ES2084190T3 (es) Utilizacion de agentes protectores contra especies de oxigeno reactivas.
SE7806939L (sv) Retentionspreparat for tandproteser
EP0673234A4 (en) TISSUE PROTECTION AND RECEIVING BLENDS.
KR970705413A (ko) 암의 광역학요법용 새로운 로다민 유도체 및 백혈병의 시험관내 정화(novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias)
DE69839586D1 (de) Verwendung von ingenan derivaten zur herstellung eines medikaments zur krebsbekämpfung
ES2136618T3 (es) Cicatrizacion de heridas.
PL264392A1 (en) A microbes killing agent
Oosterhof et al. In vivo effects of high energy shock waves on urological tumors: an evaluation of treatment modalities
NZ308391A (en) Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers
ES2133289T3 (es) Aumento en los niveles de glutation con glutamina.
IT1305306B1 (it) Uso della pirenoxina per la protezione dei tessuti corneali ininterventi di fotocheratectomia.
Lamke The influence of different “skin grafts” on the evaporative water loss from burns
DK0856312T3 (da) Anvendelse af trospiumchlorid til fremstilling af et lægemiddel til behandling af blæresygdomme
Bridge et al. Hirschmanniella miticausa n. sp.(Nematoda: Pratylenchidae) and its pathogenicity on taro (Colocasia esculenta)
JPS5562004A (en) Control agent against plant viral disease
UY26514A1 (es) " composición para el tratamiento de tejidos danados".
MILLER et al. HEALING OF SECOND DEGREE BURNS: Comparison of Effects of Early Application of Horaografts and Coverage with Tape
Stanley et al. Whitehead's varnish and Jelonet--a better dressing for skin graft donor sites than Jelonet alone.
Juchelková et al. Radioprotective Effects of Flurbiprofen and Its
EA200000762A1 (ru) Способ для консервации органов или других тканей для трансплантации
OHKOSHI Effect of aprotinin on growth of 3-methylcholanthrene-induced squamous cell carcinoma in mice
De Pasquale et al. A drug used in traditional medicine: Harpagophytum procumbens DC. III. Effects on hyperkinetic ventricular arrhythmias by reperfusion
Rice et al. The role of triglyceride accumulation and of necrosis in the hemodynamic responses of the isolated perfused rat liver after administration of carbon tetrachloride
EP0169895A1 (en) PLANT MEDICINAL COMPOSITIONS FOR THE TREATMENT OF SOME HEPATIC AND BILIARY CONDITIONS.
Sharpe et al. Stipular bud development in Danaea wendlandii (Marattiaceae)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 554381

Country of ref document: ES